MX2017008818A - Metodos para tratar enfermedades de la retina. - Google Patents
Metodos para tratar enfermedades de la retina.Info
- Publication number
- MX2017008818A MX2017008818A MX2017008818A MX2017008818A MX2017008818A MX 2017008818 A MX2017008818 A MX 2017008818A MX 2017008818 A MX2017008818 A MX 2017008818A MX 2017008818 A MX2017008818 A MX 2017008818A MX 2017008818 A MX2017008818 A MX 2017008818A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- cells
- treating
- methods
- retinal diseases
- Prior art date
Links
- 208000017442 Retinal disease Diseases 0.000 title 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 abstract 2
- 101710130208 Melanocyte protein PMEL Proteins 0.000 abstract 2
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 abstract 2
- 101710101931 Retinaldehyde-binding protein 1 Proteins 0.000 abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 101000670189 Homo sapiens Ribulose-phosphate 3-epimerase Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00727—Apparatus for retinal reattachment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Surgery (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describe un método para tratar un sujeto con degeneración macular relacionada con la edad forma seca (AMD). El método comprende administrar en la subretina del sujeto una cantidad terapéuticamente efectiva de una composición farmacéutica que comprende células RPE humanas, en donde al menos 95% de las células de la misma coexpresan proteína premelanosoma (PMEL17) y proteína de unión de retinaldehído celular (CRALBP), en donde la resistencia eléctrica transepitelial de las células es mayor que 100 ohms al sujeto, tratando por ello al sujeto. (ver Dibujo).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462097753P | 2014-12-30 | 2014-12-30 | |
| US201562116980P | 2015-02-17 | 2015-02-17 | |
| US201562116972P | 2015-02-17 | 2015-02-17 | |
| PCT/IL2015/050456 WO2016108219A1 (en) | 2014-12-30 | 2015-04-30 | Methods of treating retinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017008818A true MX2017008818A (es) | 2018-03-14 |
Family
ID=56284392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008818A MX2017008818A (es) | 2014-12-30 | 2015-04-30 | Metodos para tratar enfermedades de la retina. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20180008458A1 (es) |
| EP (1) | EP3240612B1 (es) |
| JP (4) | JP2018501281A (es) |
| KR (2) | KR102359257B1 (es) |
| CN (3) | CN107427534A (es) |
| AU (3) | AU2015373111B2 (es) |
| BR (1) | BR112017014332A2 (es) |
| CA (2) | CA3175175A1 (es) |
| DK (1) | DK3240612T3 (es) |
| EA (1) | EA201791518A1 (es) |
| ES (1) | ES2843626T3 (es) |
| HK (1) | HK1246179A1 (es) |
| IL (1) | IL253244B2 (es) |
| MX (1) | MX2017008818A (es) |
| PH (1) | PH12017501217A1 (es) |
| SG (1) | SG11201705378RA (es) |
| WO (1) | WO2016108219A1 (es) |
| ZA (1) | ZA201704359B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011063005A2 (en) | 2009-11-17 | 2011-05-26 | Advanced Cell Technology, Inc. | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
| MX2017008818A (es) | 2014-12-30 | 2018-03-14 | Cell Cure Neurosciences Ltd | Metodos para tratar enfermedades de la retina. |
| EP3916085A1 (en) | 2014-12-30 | 2021-12-01 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
| ES2774456T3 (es) | 2014-12-30 | 2020-07-21 | Cell Cure Neurosciences Ltd | Poblaciones de células del RPE y métodos de generación de las mismas |
| US11230696B2 (en) | 2015-07-29 | 2022-01-25 | Hadasit Medical Research Services And Development Ltd. | Large scale production of retinal pigment epithelial cells |
| AU2016303631B2 (en) | 2015-08-05 | 2022-07-28 | Cell Cure Neurosciences Ltd. | Preparation of photoreceptors for the treatment of retinal diseases |
| CN118021843A (zh) | 2017-03-16 | 2024-05-14 | 谱系细胞疗法公司 | 用于测量视网膜疾病疗法的疗效的方法 |
| AU2018308976A1 (en) | 2017-07-31 | 2020-02-20 | Biotime, Inc. | Compositions and methods for restoring or preventing loss of vision caused by disease or traumatic injury |
| SG11202005795TA (en) * | 2017-12-29 | 2020-07-29 | Cell Cure Neurosciences Ltd | Retinal pigment epithelium cell compositions |
| CA3097428A1 (en) | 2018-04-20 | 2019-10-24 | FUJIFILM Cellular Dynamics, Inc. | Method for differentiation of ocular cells and use thereof |
| CN108795864B (zh) * | 2018-05-24 | 2021-08-24 | 中山大学中山眼科中心 | 一种利用人诱导多能干细胞获得富含视锥及视杆细胞的类视网膜组织的方法 |
| US10264436B1 (en) * | 2018-05-29 | 2019-04-16 | Link Labs, Inc. | BLE networking systems and methods providing central and peripheral role reversal with independent peripheral network connectivity |
| CN112839682A (zh) * | 2018-08-31 | 2021-05-25 | 佛罗里达大学研究基金会有限公司 | 用于治疗卵黄状黄斑变性的腺相关病毒载体 |
| EP3969570A1 (en) * | 2019-05-15 | 2022-03-23 | Novo Nordisk A/S | Methods for obtaining eye field progenitor cells from human pluripotent stem cells |
| US20230338483A1 (en) * | 2020-09-03 | 2023-10-26 | Curebiotech Gmbh | Method for the treatment of a disease using pigment epithelium-derived factor (pedf) |
| EP3964227A1 (en) * | 2020-09-08 | 2022-03-09 | Curebiotec GmbH | Method for the treatment of a disease using pigment epithelium-derived factor (pedf) |
| KR102633321B1 (ko) * | 2021-05-11 | 2024-02-05 | 연세대학교 산학협력단 | 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물 |
| CN115212233B (zh) * | 2022-08-26 | 2024-05-28 | 北京市眼科研究所 | 用于治疗视网膜相关疾病的组合物、试剂盒及其应用 |
| WO2024110625A1 (en) * | 2022-11-24 | 2024-05-30 | Universität Bern | Cralbp based therapeutics for retinal disorders |
| KR102531735B1 (ko) * | 2022-12-27 | 2023-05-12 | 주식회사 셀리코 | 초소형 자극기 및 이의 제조방법 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| AU2008242106B2 (en) | 2007-04-18 | 2013-05-16 | Hadasit Medical Research Services And Development Ltd. | Stem cell-derived retinal pigment epithelial cells |
| WO2009051671A1 (en) * | 2007-10-12 | 2009-04-23 | Advanced Cell Technology, Inc. | Improved methods of producing rpe cells and compositions of rpe cells |
| KR101025880B1 (ko) * | 2008-10-23 | 2011-03-30 | 공희숙 | 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법 |
| WO2011063005A2 (en) * | 2009-11-17 | 2011-05-26 | Advanced Cell Technology, Inc. | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
| PT2780022T (pt) * | 2011-11-14 | 2019-07-16 | Astellas Inst For Regenerative Medicine | Preparações farmacêuticas de células epr humanas e suas utilizações |
| US9850463B2 (en) * | 2012-02-01 | 2017-12-26 | The Regents Of The University Of California | Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation |
| WO2013154336A1 (ko) * | 2012-04-09 | 2013-10-17 | 연세대학교 산학협력단 | 망막하 주사 또는 추출용 중공형 마이크로니들 및 망막하 주사기 |
| AU2014212230B2 (en) | 2013-02-01 | 2019-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem cells (iPSCs) |
| CA2933083A1 (en) * | 2013-12-11 | 2015-06-18 | Pfizer Limited | Method for producing retinal pigment epithelial cells |
| ES2774456T3 (es) | 2014-12-30 | 2020-07-21 | Cell Cure Neurosciences Ltd | Poblaciones de células del RPE y métodos de generación de las mismas |
| EP3916085A1 (en) | 2014-12-30 | 2021-12-01 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
| MX2017008818A (es) | 2014-12-30 | 2018-03-14 | Cell Cure Neurosciences Ltd | Metodos para tratar enfermedades de la retina. |
| KR101982801B1 (ko) * | 2015-10-28 | 2019-05-30 | 서울대학교 산학협력단 | 망막색소상피 분화 유도용 조성물 |
-
2015
- 2015-04-30 MX MX2017008818A patent/MX2017008818A/es unknown
- 2015-04-30 DK DK15875361.6T patent/DK3240612T3/da active
- 2015-04-30 KR KR1020177021263A patent/KR102359257B1/ko active IP Right Grant
- 2015-04-30 CA CA3175175A patent/CA3175175A1/en active Pending
- 2015-04-30 CN CN201580076318.0A patent/CN107427534A/zh active Pending
- 2015-04-30 SG SG11201705378RA patent/SG11201705378RA/en unknown
- 2015-04-30 BR BR112017014332A patent/BR112017014332A2/pt not_active Application Discontinuation
- 2015-04-30 WO PCT/IL2015/050456 patent/WO2016108219A1/en active Application Filing
- 2015-04-30 EP EP15875361.6A patent/EP3240612B1/en not_active Revoked
- 2015-04-30 CN CN202210141757.7A patent/CN114533761A/zh active Pending
- 2015-04-30 KR KR1020227003550A patent/KR102514912B1/ko active IP Right Grant
- 2015-04-30 IL IL253244A patent/IL253244B2/en unknown
- 2015-04-30 EA EA201791518A patent/EA201791518A1/ru unknown
- 2015-04-30 ES ES15875361T patent/ES2843626T3/es active Active
- 2015-04-30 JP JP2017535831A patent/JP2018501281A/ja active Pending
- 2015-04-30 CN CN202210144880.4A patent/CN114469998A/zh active Pending
- 2015-04-30 US US15/539,565 patent/US20180008458A1/en not_active Abandoned
- 2015-04-30 AU AU2015373111A patent/AU2015373111B2/en active Active
- 2015-04-30 CA CA2972700A patent/CA2972700A1/en not_active Abandoned
-
2017
- 2017-06-27 ZA ZA2017/04359A patent/ZA201704359B/en unknown
- 2017-06-29 PH PH12017501217A patent/PH12017501217A1/en unknown
-
2018
- 2018-05-03 HK HK18105715.3A patent/HK1246179A1/zh unknown
-
2020
- 2020-05-27 JP JP2020092030A patent/JP2020143137A/ja not_active Withdrawn
-
2021
- 2021-09-08 AU AU2021229196A patent/AU2021229196A1/en not_active Abandoned
-
2022
- 2022-07-04 JP JP2022107516A patent/JP2022125160A/ja active Pending
- 2022-09-13 US US17/943,462 patent/US20230028133A1/en active Pending
-
2023
- 2023-10-27 AU AU2023255009A patent/AU2023255009A1/en not_active Abandoned
- 2023-12-11 JP JP2023208119A patent/JP2024023611A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501217A1 (en) | Methods of treating retinal diseases | |
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2022013517A (es) | Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas. | |
| MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
| WO2017136795A8 (en) | Bacteria engineered to treat diseases associated with tryptophan metabolism | |
| WO2015165413A8 (zh) | 一种新型的稳定型抗体药物耦联物及其制备方法和用途 | |
| MX2019007352A (es) | Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares. | |
| WO2016210384A3 (en) | Bacteria engineered to treat metabolic diseases | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
| MX2019015311A (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
| PH12016502015A1 (en) | Anti-factor d antibody variants and uses thereof | |
| MX2016006271A (es) | Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| WO2017139697A8 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| WO2016200614A3 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| MX2016010328A (es) | Tratamiento con halogeno de ataque cardiaco y lesion isquemica. | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| WO2015099838A3 (en) | Compositions and methods of treating ocular diseases | |
| MX2018005460A (es) | Composicion de feromona para estimular reproduccion de hembras suids y metodos de uso. | |
| EP3176163A4 (en) | Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient | |
| GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| EP3337482A4 (en) | TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS | |
| EP3416500A4 (en) | DRUG COMBINATIONS AND METHODS FOR STIMULATING EMBRYO-LIKE REGENERATION TO TREAT DIABETES AND OTHER DISEASES |